Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Fernando Galanternik
Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine
Cancer Management and Research
Oncology
Related publications
Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
International Journal of Breast Cancer
Cancer Research
Oncology
Pharmacology
Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer
Biochimica et Biophysica Acta - Reviews on Cancer
Cancer Research
Oncology
Genetics
Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
New England Journal of Medicine
Medicine
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Molecular Cancer Therapeutics
Cancer Research
Oncology
P3-013a Phase 1b Study of S-1 Combined With Trastuzumab Emtansine (T-Dm1) for HER2 Positive Metastatic Breast Cancer
Annals of Oncology
Medicine
Oncology
Hematology
Src, a Potential Target for Overcoming Trastuzumab Resistance in HER2-positive Breast Carcinoma
British Journal of Cancer
Cancer Research
Oncology
Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib
AboutOpen
A Randomized, Controlled Phase II Trial of Neoadjuvant Ado-Trastuzumab Emtansine, Lapatinib, and Nab-Paclitaxel Versus Trastuzumab, Pertuzumab, and Paclitaxel in HER2-positive Breast Cancer (TEAL Study)
Breast Cancer Research
Cancer Research
Oncology
Relationship Between Tumor Biomarkers and Efficacy in MARIANNE, a Phase III Study of Trastuzumab Emtansine ± Pertuzumab Versus Trastuzumab Plus Taxane in HER2-positive Advanced Breast Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
